Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORKA-001 OLE in Moderate-to-Severe Plaque Psoriasis
NCT07449702Phase 2Recruiting
- Sponsor
- Oruka Therapeutics
- Start
- Feb 2026
- Primary completion
- May 2030
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of orka-001 in plaque psoriasis, sponsored by Oruka Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
orka-001
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07449702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449702.